INTRODUCTION
Gentamicin, along with ampicillin, is widely used in full-term neonates as empirical therapy for presumed early-onset sepsis because the combination is synergistic against common etiologic agents prevalent in this age group. 1, 2 Similar to other aminoglycosides, gentamicin has a narrow therapeutic index, 3 and monitoring of serum concentrations is essential to ensure optimum therapeutic concentrations and to avoid the likelihood of nephrotoxicity and ototoxicity. Studies have suggested the importance of achieving high therapeutic serum gentamicin concentration (SGC) at the outset of therapy for improving the outcome of patients with Gram-negative infections. 4, 5 Grasso et al., 6 in their in vitro model, showed that a high peak gentamicin concentration is the main determinant for antibacterial activity. Studies in adult patients have demonstrated high-dose, extended-interval dosing of aminoglycosides to be more efficacious and potentially less toxic compared to multiple daily doses. 7 -9 However, data in neonates are sparse and neonatal reference books continue to suggest varying dose schedules for full-term infants. 1, 10, 11 The aim of our study was to establish a uniform once-daily dose regimen for gentamicin for full-term neonates and compare its pharmacokinetics with that of traditional twice-daily dose regimen. For this purpose, we chose to evaluate the new dose schedule of gentamicin, i.e., 4 mg/kg given at 24-hour intervals, as recommended recently by Neofax, 12 a neonatal formulary book widely used for reference purposes. We compared this schedule with the traditional dose schedule of gentamicin, i.e., 2.5 mg/kg given at 12-hour intervals.
11,13

METHODS
This study was designed as a prospective, randomized, controlled trial and was conducted in the Neonatal Intensive Care Unit (NICU) of
OBJECTIVE:
There is no uniformity in the current recommendations of dosing regimen of gentamicin for neonates. We conducted a prospective, randomized, controlled trial to compare a once -daily dosing regimen to the twice -daily dosing regimen for neonates !2500 g during the first 7 days after birth.
STUDY DESIGN:
Infants !2500 g admitted to the Neonatal Intensive Care Unit and prescribed gentamicin for suspected bacterial infection were randomized to receive either 4 mg / kg every 24 hours, study group ( n = 20 ), or a standard regimen of 2.5 mg / kg every 12 hours, control group ( n = 21 ). Serum gentamicin concentrations ( SGCs ) were followed and gentamicin pharmacokinetics calculated on all infants.
RESULTS:
Peak SGC 30 minutes after the first dose was 8.2 ± 1.7 g / ml in the study group, compared to 6.4 ± 1.5 g / ml in the control group ( p = 0.001 ). Ninety -five percent of study group infants, compared to 81% of the control group, had peak SGCs in therapeutic range after the first dose. Peak SGC at 48 hours ( steady state ) was 8.9 ± 1.5 in the study group and 6.8 ± 1.1 in the control group ( p = 0.0001 ). On further analysis, a significantly higher percentage of infants in the study group, compared to the control group, had peak SGCs in higher therapeutic ranges of 6 to 12 g / ml as well as 8 to 12 g / ml. None of the study infants, compared to six control infants, had trough SGCs !2 g / ml at steady state. Thus, none of the study group infants, versus six of the control group infants, needed a dosing adjustment at 48 hours ( p = 0.02, Fisher's exact test ).
CONCLUSION:
We found that 4 mg / kg gentamicin given every 24 hours achieved significantly higher peak SGCs and safe trough concentrations in all infants, compared to the twice -daily regimen of 2.5 mg / kg. We suggest that SGCs may not need to be followed in term infants prescribed a short course of this once -daily regimen for suspected early -onset sepsis if renal functions are normal. Infants were randomly assigned to either study group or control group by picking up a preassigned sealed envelope containing consecutive infant numbers. For each number, a corresponding assignment, ''study'' or ''control,'' was randomly ordered as per a computer-generated list. The study group infants were given gentamicin at 4 mg/kg per dose every 24 hours 12 and the control group infants were given gentamicin at 2.5 mg/kg per dose every 12 hours. 13 Neofax has recommended that !37 weeks 13 and !38 weeks 12 be used to define full-term infants. However, we used birth weight of !2500 g as a convenient and duplicable characteristic for the term and near-term infants because a majority of our mothers did not have accurate dates. Gentamicin was infused over a 30-minute period with a metered syringe pump using a microbore tubing. The tubing was flushed with routine flush solution after completion of infusion. All infants were concomitantly treated with ampicillin.
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Data Collection
The following infant demographic profile was collected: gestational age as determined by maternal history and confirmed by physical and neurological exam based on Dubowitz gestational age assessment, 14 birth weight, length, weight for gestational age, mode of delivery, APGAR scores at 1 and 5 minutes, and postnatal age at the time of initiation of therapy. Presence of patent ductus and concurrent use of any nephrotoxic medications in the infant were also recorded. The maternal demographic profile included: history of prolonged rupture of membranes; chorioamnionitis; use of nephrotoxic medications, such as aminoglycosides, diuretics, and indomethacin; and events, if any, that may affect the fetal renal functions.
A complete blood count, blood culture, and urine latex antigen for group B Streptococcus were done as a part of sepsis work up and were recorded in the data sheet. Serial CBCs, urine culture, and CSF results were also recorded, if requested by the treating physician, based on clinical indications. Renal functions were monitored by measuring 24-hour urine output on days 1, 2, and 3 of therapy. Serum electrolytes, blood urea nitrogen, and serum creatinine were measured on days 2 and 3 of the study. Urine sodium and urine creatinine were measured on days 2 and 3 of therapy.
SGCs
Blood for peak SGC was drawn 30 minutes after completion of the gentamicin infusion and, for trough concentration, 30 minutes prior to the start of gentamicin infusion. SGCs were measured after the first dose and before and after the doses at 24 and 48 hours in the study group and after the first dose and before and after the doses at 12, 24, and 48 hours in the control group. To compare gentamicin pharmacokinetics, an additional SGC was measured 11 hours after completion of the first dose of gentamicin in the study group and was labeled as midpoint. This SGC corresponded to the trough SGC in the control group taken before the dose at 12 hours. Trough and peak SGCs drawn with the dose at 48 hours were considered to reflect steady state.
SGCs were measured by fluorescence polarization immunoassay analyzer (Abbott, Axsym, Abbott Park, IL). Serum levels of <0.3 g/ml were reported as 0.3 g/ml. The coefficient of variation was 9.5% at a concentration of 1.15 g/ml and 7.9% at a concentration of 7.3 g/ml. Serum creatinine, urine sodium, and urine creatinine were measured by Kinetic Alkaline Picrate methods using Olympus AV600.
Therapeutic SGCs
Peak SGC between 5 and 12 g/ml and trough SGC of <2 g/ml were considered therapeutic. 12, 15, 16 Dose adjustments were made during the first 48 hours of study if peak SGC was <5 g/ml and infant had abnormal white blood cell count or positive blood culture or definite evidences of sepsis. Dose adjustments were also made during this time if gentamicin peak level was >12 g/ml and/or a trough level was !2 g/ml and there were signs of renal insufficiency as indicated by high serum creatinine (>1.0 mg/dl), or an increase in the serum creatinine value by >0.5 mg/dl or unexplained polyuria as defined by urine output of >4 ml/kg per hour or oliguria as defined by urine output of <1 ml/kg per hour.
Pharmacokinetics of Gentamicin
Individual pharmacokinetics measurements were done using one compartment open linear model. The elimination rate constant (k) for gentamicin was calculated by using the following formula: k=(C p max /C p min )ln/time interval between two serum concentrations, where C p max is peak SGC, C p min is trough SGC, and ln is natural log. The biological half-life of gentamicin was calculated as 0.693/k. The volume of distribution (V d , l/kg) for gentamicin was calculated as V d =dose per kg/(C p max ÀC p min ).
Hearing screen was done in all infants using the Natus ALGO infant hearing screener. The result is displayed as Pass/Refer for individual ear. The sensitivity of the result is 98% and specificity 96%. Hearing screens were performed on all infants prior to discharge from the NICU.
Statistical Analysis
The trial was proposed as a pilot study. We planned to enroll 20 infants in each arm of the study. Allowing for attrition and exclusion from the study, we initially planned to enroll 10% more than the requisite number. Statistical analysis was performed after enrollment of all infants. All data were entered on an SPSS program. Statistical analysis was performed using chi-square test and Fisher's exact test if necessary for discrete variables, and two-way analysis of variance for continuous variables. p<0.05 was considered significant.
RESULTS
Forty-four infants met the criteria and were enrolled in the study. Three infants were excluded after enrollment: parents of two infants withdrew consent, and a third infant was excluded because the initial blood sample was lost. Thus, there were 41 infants: 20 in the study group and 21 in the control group. All infants were enrolled within the first 24 hours after birth. Table 1 lists the demographic profile of the two groups. The groups were comparable in regard to birth weight, gestational age, APGAR scores, postnatal age, and diagnosis of, or severity of, neonatal illness. Two infants in each group required inotropes for hypotension.
SGCs
As expected, the peak SGCs at all times were significantly higher in the study group compared to the control group (Table 2 ). All but one infant (4.78 g/ml) in the study group achieved therapeutic concentrations (5-12 g/ml) immediately after the first dose compared to 17 infants (81%) in the control group ( Figure 1A) . Subsequently, none of the infants in the study group had subtherapeutic SGCs, whereas in the control group, two infants at 24 hours and one infant at 48 hours still had subtherapeutic SGCs ( Figure 1C) .
On further analysis, 93% of all peak SGCs in the study group was in a higher therapeutic range of 6 to 12 g/ml 11 compared to 57% in the control group ( p=0.0001) ( Table 2) . The difference was not significant between the two groups after the first dose, but a significantly higher percentage of infants in the study group compared to the control group had peak SGCs between 6 and 12 g/ ml after the doses at 24 and 48 hours. In addition, a significantly higher percentage of infants in the study group compared to the control group had peak SGCs between 8 and 12 g/ml range at each time point studied (Figure 2) .
None of the infants in either group had toxic peak SGCs of >12 g/ml at any time point (Figure 1, A and C) . None of the infants in the study group had a potentially toxic trough concentration of !2 g/ml before the 24-hour dose or before the dose at 48 hours. In contrast, nine control infants at 24 hours (43%) ( p=0.001) and six infants at 48 hours (29%) ( p=0.02) had potentially toxic trough SGCs ( Figure 1B) . Thus, six control infants (29%) compared to none of the study infants required a change in dosing schedule after the dose at 48 hours ( p=0.02). *Number of infants with abnormal SGCs, i.e., trough !2 g/ml and/or peak !12 g/ml.
MP, midpoint SGC in study group corresponding to the trough concentration in the control group.
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One of these control infants also had subtherapeutic peak SGC at 48 hours. Two infants in the study group prior to the dose at 24 hours and one infant prior to the dose at 48 hours had trough SGC of <0.5 g/ml ( Figure 1B) , whereas none of the infants in the control group had such extremely low trough SGCs at any time.
Infants <37 weeks of gestation had similar trough and peak SGCs as their term counterparts, and excluding these infants did not change results. However, our results should not be extrapolated for preterm infants because we had only a small number of infants <37 weeks of gestation (Table 1) .
Gentamicin Pharmacokinetics
No differences were found between the two groups for gentamicin half-life (5.82±1.7 and 5.46±1.4 hours for the study and the control groups, respectively) or elimination rate constant (0.13±0.03 and 0.14±0.05 hours; study versus control).
Blood cultures in two control group infants grew group B Streptococcus. None of the study group infants had positive blood cultures. There were no differences in urine output, serum creatinine, or creatinine clearance between the two groups ( Table 3 ). All infants passed a hearing screen test done prior to the discharge from hospital.
DISCUSSION
Our study demonstrates that once-daily dose of 4 mg/kg gentamicin achieved significantly higher peak SGCs and safe trough SGCs in all infants compared to the twice-daily regimen of 2.5 mg/ kg. None of the infants receiving once-daily dose required an adjustment in dosing compared to nearly 30% of those receiving twice-daily dosing ( p=0.02). Since the original article by McCracken and Jones, 17 several gentamicin dosing regimens have been recommended in an attempt to achieve optimal therapeutic serum concentrations. It has been shown that clinical response to aminoglycosides, such as gentamicin, depends on the peak serum concentrations and the peak-to-MIC ratio. 4, 18 The clinical outcome was better and the mortality rate lower in adult patients with pneumonia or sepsis caused by Gram-negative bacteria when peak serum aminoglycoside concentrations exceeded 5 g/ml during the first day of treatment. 4, 18 The mortality rate was only 2.4% when gentamicin or tobramycin peak concentrations drawn 1 hour after a 30-minute infusion exceeded 5 g/ml compared to 21% among patients with peak SGC of <5 g/ml after the first dose. 4 This observation was supported by Noone et al. 5 who reported an 88% cure rate if peak SGCs were !5 g/ml in patients with bacteremia and !8 g/ml in patients with pneumonia compared to only 12% cure rate if peak SGCs were below these ranges during first 72 hours of therapy. A higher-dosage, extended-interval regimen of gentamicin in neonates !2500 g allows higher peak serum concentrations that are now considered therapeutic and yet avoids cumulation of drug.
The need to achieve serum therapeutic concentrations immediately after the first dose is not addressed by the currently available dosing recommendations for neonates. 10, 11 To achieve high peak SGC in neonates, several investigators have tried a loading dose of 5 mg/kg in neonates. 16, 19 However, what subsequent doses should be used is not clear. In our study, 95% of infants receiving gentamicin at 4 mg/kg at 24-hour intervals achieved therapeutic SGCs after the first dose compared to 81% of the infants in the control group. None of the infants in the study group had SGCs of <5 g/ml at 24 and 48 hours, whereas in the control group, two infants at 24 hours (9.5%) and one infant at 48 hours (4%) still had SGCs of <5 g/ml.
The bactericidal activity of aminoglycosides, such as gentamicin, not only depends on peak SGC but also on the ratio of peak SGC to MIC for a given microbe. Moore et al., 18 in a post hoc analysis of four randomized, double-blind, controlled trials of aminoglycosides for the treatment of Gram-negative sepsis, demonstrated a graded doseresponse effect between an increasing peak concentration-to-MIC ratio and the clinical response. The response rate in their study was approximately 90% when peak-to-MIC ratio was 8 to 12. None of our infants suffered from Gram-negative sepsis, but we speculate that the gentamicin dose of 4 mg/kg given at 24-hour intervals to infants !2500 g would be potentially more efficacious in infants with such infections sensitive to gentamicin even at a MIC of 1 g/ ml because a significantly higher percentage of infants in the study group, compared to the control group, had peak SGCs between 8 and 12 g/ml (Figure 2 ).
Several studies in the last decade have examined SGCs in neonates; however, some have used extremely small sample size 20 and others are not prospectively designed in a randomized manner. 21 -24 A recent study by Thureen et al. 21 used once-daily versus twice-daily dose in neonates !34 weeks of gestation. The dosing regimen was similar to our study. Infants were prospectively temporally allocated to receive one of the two regimens in this cohort study. However, 50% of the infants in their study receiving twice-daily dose were <37 weeks of gestation, whereas only 26% of those receiving once-daily dose were preterm, suggesting a bias toward administering twice-daily dose to preterm infants. Similar to our findings, Thureen et al. showed that traditional regimen of 2.5 mg/ kg given at 12-hour intervals achieved significantly lower peak SGCs compared to the group receiving 4 mg/kg at 24-hour intervals. Lundergan et al., using a bolus gentamicin dose of 5 mg/kg followed by 4 mg/kg in term infants !2500 g, also showed significantly higher peak SGCs compared to the historical controls who were given 2.5 mg/kg at 12-hour intervals. 23 A significantly higher percentage of infants in the control group compared to the study group had potentially toxic trough SGCs. This finding is particularly important in clinical management. Mean trough concentrations were also significantly lower in the Creatinine clearance, as calculated by UV / P of creatinine; FENa, fractional excretion of sodium as calculated by U / P sodiumÄU / P creatinineÂ100. There were no significant differences between the groups at a p level of 0.05.
study group compared to the control group. Recently, Hayani et al. 20 studied gentamicin pharmacokinetics in term infants. They randomized 11 infants to receive 5 mg/kg every 24 hours and 16 infants to receive 2.5 mg/kg every 12 hours. Infants were given gentamicin either intramuscularly or intravenously. The authors found similar trough concentrations between the two groups. However, the difference in trough concentrations might have been missed in their study because of the small sample size and further dichotomizing the groups for the route of administration. Our study confirms the findings of Thureen et al. 21 and Lundergan et al., 23 who also found significantly lower trough concentrations and a lower incidence of potentially toxic trough concentrations in infants receiving once-daily dose of gentamicin compared to those receiving twice-daily dose. Using the currently available guidelines for therapeutic range, we found that approximately a third of the infants in the control group, compared to none in the study group, required a modification in the gentamicin dosing ( p=0.02). This finding is similar to findings of Lundergan et al. 23 who reported a comparative cohort study recently. Approximately 45% of term infants who received twice-daily dose of 2.5 mg/kg gentamicin required a change in dosing regimen in their study compared to none of the infants who received 5 mg/kg as initial bolus followed by 4 mg/kg at 24-hour intervals. These findings might obviate the need to follow SGCs in term infants who are given a 2-or 3-day course of gentamicin to rule out sepsis. We recommend that SGCs should still be followed in term infants who receive gentamicin for a longer duration or those who have a predisposition to abnormal renal functions, e.g., infants with perinatal asphyxia or low APGAR scores.
The significance of the low trough SGCs ( <0.5 g/ml) found in a small percentage of the study infants is not clear at this time. Young and Mangum 12 have recently recommended a trough level of 0.5 to 1.0 g/ml as therapeutic, but there is no support in the literature for this recommendation. Aminoglycosides, such as gentamicin, induce postantibiotic effect and continue to inhibit growth of Gram-negative organisms for up to 7 hours after the exposure to minimal inhibitory concentrations of aminoglycosides. 25 The length of postantibiotic effect appears to be dose-dependent. The long postantibiotic effect of aminoglycosides after exposure to high serum drug concentrations suggests that regimens recommending higher doses of gentamicin given at longer intervals will potentially be more efficacious in neonates with Gram-negative infections.
We conclude that 4 mg/kg gentamicin given at 24-hour intervals to neonates !2500 g at birth in the immediate neonatal period achieves early therapeutic peak serum concentration and safe trough concentrations in all infants compared with the conventional twicedaily regimen of 2.5 mg/kg given at 12-hour intervals. Whether this once-daily regimen of 4 mg/kg in term infants will improve clinical outcome in proven Gram-negative infections requires further studies with an extremely large sample size as only a very small percentage of infants have such infections. However, extrapolating data from adults and animal studies, this regimen may be most appropriate. Additionally, it will reduce hospital expenses by cutting the cost of material, labor, and processing.
